Stoke Therapeutics Inc (STOK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has a cash flow conversion efficiency ratio of -0.153x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-60.58 Million) by net assets ($394.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See STOK defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Stoke Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Stoke Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Stoke Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stoke Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allied Machinery Co. Ltd.
SHG:605060
|
N/A |
|
Firstsource Solutions Limited
NSE:FSL
|
0.102x |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
0.020x |
|
Pharvaris BV
NASDAQ:PHVS
|
-0.098x |
|
Hunan Kaimeite Gases Co Ltd
SHE:002549
|
0.034x |
|
Shenzhen Ysstech Info-Tech Co Ltd
SHE:300377
|
-0.089x |
|
Megaport Ltd
AU:MP1
|
0.069x |
|
Omnicell Inc
NASDAQ:OMCL
|
0.025x |
Annual Cash Flow Conversion Efficiency for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Stoke Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see STOK market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $352.46 Million | $45.59 Million | 0.129x | +134.10% |
| 2024-12-31 | $229.02 Million | $-86.85 Million | -0.379x | +25.36% |
| 2023-12-31 | $159.56 Million | $-81.07 Million | -0.508x | -194.71% |
| 2022-12-31 | $184.85 Million | $-31.87 Million | -0.172x | +43.89% |
| 2021-12-31 | $217.78 Million | $-66.91 Million | -0.307x | -108.17% |
| 2020-12-31 | $286.08 Million | $-42.22 Million | -0.148x | -6.66% |
| 2019-12-31 | $224.43 Million | $-31.05 Million | -0.138x | -32.60% |
| 2018-12-31 | $105.07 Million | $-10.96 Million | -0.104x | -102.50% |
| 2017-12-31 | $-1.29 Million | $-5.38 Million | 4.167x | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more